Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

1(16.7%)

Phase 3

1(16.7%)

N/A

1(16.7%)

6Total

Phase 2(3)

Phase 1(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02330926Phase 3Completed

Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy

Role: collaborator

NCT03333785Not ApplicableCompleted

Randomized Trial of eOncoNote

Role: collaborator

NCT00002487Phase 2Unknown

Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer

Role: lead

NCT00002887Phase 1Unknown

Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer

Role: lead

NCT00002488Phase 2Unknown

Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy

Role: lead

NCT00002608Phase 2Completed

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Role: lead

NCT00750672Completed

Follow-up Care After Treatment for Endometrial Cancer

Role: collaborator

All 7 trials loaded